Study guide
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations
Key Takeaways Explain This Topic AI
Under revised USP <795>, default Beyond-Use Dates (BUD) for oral formulations in the absence of stability data are governed by water activity (a_w): non-preserved aqueous oral liquids carry a maximum BUD of 14 days refrigerated (2°C–8°C), preserved aqueous oral liquids carry a maximum BUD of 35 days (controlled room temperature or refrigerated), and non-aqueous oral formulations carry up to 90 days.
Commercial vehicle Ora-Plus is a thixotropic suspending vehicle buffered to pH 4.0–4.5 containing microcrystalline cellulose, sodium carboxymethylcellulose, and xanthan gum; it is mixed 1:1 with Ora-Sweet (sucrose syrup) or Ora-Sweet SF (sugar-free) to maintain uniform physical suspension and chemical stability.
Peer-reviewed compounding stability studies must utilize validated, stability-indicating High-Performance Liquid Chromatography (HPLC) assays demonstrating baseline resolution of parent drug from forced degradation products, alongside physical redispersibility and USP <51> antimicrobial effectiveness testing.
Crushing modified-release solid dosage forms—specifically enteric-coated (EC), extended-release (ER/XR/CR), osmotic release oral systems (OROS), and microencapsulated beads—is strictly contraindicated due to catastrophic dose dumping, gastric acid inactivation, or severe gastrointestinal mucosal ulceration.
Last updated: September 2026
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations
Pediatric pharmacotherapy is constrained by a profound shortage of commercially available, age-appropriate liquid formulations. More than 40% of medications administered to hospitalized pediatric and neonatal patients must be compounded or manipulated extemporaneously to achieve weight-based dosing (mg/kg or mg/m²). When preparing non-sterile pediatric liquids, clinical pharmacists must apply the revised United States Pharmacopeia (USP) Chapter <795> standards, select chemically compatible suspending vehicles, critically appraise stability-indicating analytical literature, and identify non-crushable solid dosage forms to prevent fatal formulation errors.
USP <795> Regulatory Framework & Default Beyond-Use Dating (BUD)
Under revised USP <795> (effective November 1, 2023), default Beyond-Use Dates (BUD) for non-sterile compounded preparations (CNSPs) packaged in tight, light-resistant containers are established based on water activity ( a w a_w a w ) , presence of antimicrobial preservatives, route of administration, and storage temperature, in the absence of published stability-indicating data or specific USP-NF monographs. USP <795> Water Activity Classification & Default Oral Liquid BUDs:
- ┌──────────────────────────────────────┬─────────────┬──────────────────────┬──────────────┐
- │ Formulation Type │ Water Act. │ Storage Temperature │ Maximum BUD │
- ├──────────────────────────────────────┼─────────────┼──────────────────────┼──────────────┤
- │ Non-Preserved Aqueous Oral Liquid │ aw ≥ 0.60 │ Refrigerated (2°–8°C)│ 14 Days │
- │ Preserved Aqueous Oral Liquid │ aw ≥ 0.60 │ Room Temp or 2°–8°C │ 35 Days │
- │ Non-Aqueous Oral Formulation │ aw < 0.60 │ Room Temp or 2°–8°C │ 90 Days │
- │ Non-Aqueous Topical / Mucosal Form │ aw < 0.60 │ Room Temp or 2°–8°C │ 180 Days │
- └──────────────────────────────────────┴─────────────┴──────────────────────┴──────────────┘
- Water Activity ( a w a_w a w ) and Critical Constraints
Aqueous Formulations ( a w ≥ 0.60 a_w \ge 0.60 a w ≥ 0.60 ): Water activity measures the unbound, free water available for microbial proliferation and hydrolytic degradation. Oral suspensions, solutions, and emulsions prepared with water, syrups, or aqueous commercial vehicles fall into this category.
Non-Preserved Aqueous Oral Liquids: Maximum BUD is 14 days under refrigeration (2°C to 8°C) . Storing non-preserved aqueous liquids at room temperature is non-compliant due to rapid bacterial and fungal proliferation.
Preserved Aqueous Oral Liquids: Formulations containing validated antimicrobial preservatives (e.g., potassium sorbate, sodium benzoate, methylparaben, propylparaben) have a maximum BUD of 35 days at either Controlled Room Temperature (CRT, 20°C to 25°C) or under refrigeration (2°C to 8°C).
Non-Aqueous Formulations ( a w < 0.60 a_w < 0.60 a w < 0.60 ): Systems formulated with non-aqueous vehicles (e.g., fixed vegetable oils, medium-chain triglycerides, polyethylene glycol [PEG], mineral oil, or dry powders in gelatin/HPMC capsules). Oral non-aqueous forms carry a default BUD of up to 90 days at CRT or refrigerated; non-aqueous topical or mucosal forms carry up to 180 days .
Starting Component Expiration Limits: The assigned BUD must never exceed the shortest remaining expiration date of any starting component, active pharmaceutical ingredient (API), or commercial product used in compounding. If commercial tablets expiring in 20 days are crushed into a preserved vehicle, the maximum permissible BUD is 20 days, not 35 days.
Commercial Pediatric Suspending Vehicles & Compounding Chemistry
When converting insoluble solid dosage forms into homogeneous oral liquids, selecting the correct suspending vehicle is critical to prevent irreversible sedimentation, maintain physical redispersibility, and buffer the active drug at its optimum stability pH.
Commercial Vehicle Key Excipients & Composition Buffered pH Rheological Mechanism & Clinical Application
Ora-Plus Microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, carrageenan, citric acid, sodium phosphate, antifoaming agent 4.0–4.5 Thixotropic suspending vehicle. Forms a gel structure at rest that prevents particulate sedimentation; thins under agitation/shear for uniform pouring. Must be blended 1:1 with flavoring syrup.
Ora-Sweet Sucrose (approx. 70%), glycerin, sorbitol, sodium phosphate, citric acid, potassium sorbate, methylparaben, berry flavoring 4.0–4.5 Flavored syrup vehicle. Provides sweetness, viscosity, and antimicrobial preservation. Combined 1:1 with Ora-Plus to formulate oral suspensions.
Ora-Sweet SF Glycerin, sorbitol, sodium saccharin, xanthan gum, citric acid, sodium citrate, potassium sorbate, propylparaben, methylparaben 4.0–4.5 Sugar-free syrup vehicle. Formulated for ketogenic diets, diabetic pediatrics, and fluid-restricted intensive care. Mixed 1:1 with Ora-Plus.
SyrSpend SF Modified food starch, sucralose, citric acid, sodium benzoate (or preservative-free) 4.2–4.6 Starch-based suspending vehicle. Available in preserved liquid (cherry or unflavored) and preservative-free liquid; neutral osmolality reduces gastrointestinal osmotic diarrhea.
SyrSpend SF Alka Modified food starch, sucralose, sodium bicarbonate Alkaline (pH > 7.0) Dry powder reconstitutable vehicle. Contains sodium bicarbonate buffer to protect acid-labile proton pump inhibitors (omeprazole, lansoprazole) from gastric degradation without requiring enteric coatings.
Flocculation, Sedimentation & Rheology
An ideal pharmaceutical suspension is flocculated : particles form loose, macroscopic aggregates (flocs) governed by secondary van der Waals attractive forces. Although flocculated suspensions settle relatively rapidly, they create a large, porous sediment volume ( F ≈ 1 F \approx 1 F ≈ 1 ) that redisperses completely upon gentle shaking : Sedimentation Volume Ratio ( F ) = Ultimate Volume of Sediment ( V u ) Initial Total Volume of Suspension ( V o ) \text{Sedimentation Volume Ratio } (F) = \frac{\text{Ultimate Volume of Sediment } (V_u)}{\text{Initial Total Volume of Suspension } (V_o)} Sedimentation Volume Ratio ( F ) = Initial Total Volume of Suspension ( V o ) Ultimate Volume of Sediment ( V u )
Conversely, deflocculated suspensions settle slowly into a dense, tightly packed sediment where repulsive zeta potentials are overcome, forming an irreversible "cake" that cannot be resuspended even with vigorous shaking. Inadvertent administration of a caked suspension results in catastrophic under-dosing initially, followed by a lethal overdose when the dense sediment at the bottom of the bottle is drawn up.
Common Pediatric Formulations & Dosing Scenarios
Spironolactone Oral Suspension (5 mg/mL or 25 mg/mL): Used for congestive heart failure and bronchopulmonary dysplasia (dosing: 1 to 3 mg/kg/day divided every 12 to 24 hours ; maximum 100 mg/day). Compounded by crushing spironolactone tablets in a 1:1 mixture of Ora-Plus and Ora-Sweet (or Ora-Sweet SF). Multiple peer-reviewed studies confirm chemical stability for 60 days at controlled room temperature or refrigerated.
Ursodiol Oral Suspension (50 mg/mL): Indicated for parenteral nutrition-associated cholestasis (PNAC) and biliary atresia (dosing: 10 to 30 mg/kg/day divided every 8 to 12 hours ). Compounded in Ora-Plus:Ora-Sweet (1:1); stable for 60 days at CRT or refrigerated.
Baclofen Oral Suspension (5 mg/mL): Used for pediatric cerebral palsy spasticity (starting at 0.3 to 0.75 mg/kg/day divided every 8 hours , titrating to 1 to 2 mg/kg/day; maximum 40 to 60 mg/day). Stable in Ora-Plus:Ora-Sweet (1:1) for 60 days at CRT or refrigerated.
Evaluating Peer-Reviewed Stability Studies
Clinical pharmacists must distinguish between valid, peer-reviewed stability studies (published in journals such as the American Journal of Health-System Pharmacy [AJHP] or International Journal of Pharmaceutical Compounding [IJPC]) and simple anecdotal recipes. To support extending a BUD beyond default USP <795> limits, a published study must meet three rigorous criteria: Core Criteria for Validating Compounding Stability Literature:
1. Validated Stability-Indicating HPLC Assay:
- Baseline chromatographic resolution of intact parent API from degradation peaks.
- Forced degradation stress testing: acid (HCl), base (NaOH), thermal, photolytic, and oxidative (H2O2).
2. Physical Stability & Rheological Integrity:
- Documented visual uniformity, color, odor, redispersibility (<10-15 inversions), and absence of caking.
- Strict maintenance of pH within ±0.5 units of baseline throughout study duration.
3. Antimicrobial Preservative Effectiveness (USP <51>):
- Inoculation challenge demonstrating specified log-reductions against:
S. aureus, P. aeruginosa, E. coli, C. albicans, and A. brasiliensis.
Analytical Pitfalls in the Literature
Spectrophotometric (UV-Vis) Flaws: Simple UV-Vis spectrophotometry measures total light absorbance at a fixed wavelength. Degradation products often retain the parent drug's chromophore, yielding falsely elevated "100% active drug" readings in decomposed samples. Non-chromatographic assays are invalid for BUD extension.
Packaging & Sorption: Studies must evaluate the exact container-closure system used in clinical practice (e.g., amber polyethylene terephthalate [PET] vs high-density polyethylene [HDPE] bottles vs clear oral syringes). Lipophilic active drugs (e.g., diazepam, vitamin A) adsorb significantly to plastic walls, reducing delivered potency.
Identifying Non-Crushable Solid Dosage Forms
Crushing tablets or opening capsules to compound oral liquids or administer via enteral feeding tubes (nasogastric, gastrostomy, jejunostomy) carries severe clinical hazards when applied to modified-release or coated solid dosage forms.
Formulation Category Suffixes / Acronyms Mechanism & Clinical Purpose Consequence of Crushing / Manipulating
Extended-Release ER, XR, XL, CR, SR, LA, CD, TR Delivers total 12- to 24-hour drug payload continuously via polymer matrix or coating Dose Dumping: Immediate release of entire 24-hour dose, causing acute toxicity, profound sedation, severe hypotension, or death (e.g., nifedipine ER, morphine ER).
Enteric-Coated (Delayed-Release) EC, DR, EN Acid-resistant polymer barrier (e.g., cellulose acetate phthalate) dissolves only at alkaline duodenal pH ( > 5.5 >5.5 > 5.5 ) Acid Inactivation & Mucosal Injury: Gastric acid denatures drug (e.g., pancrelipase, omeprazole) or drug causes severe gastric ulceration and emesis (e.g., bisacodyl, EC aspirin).
Osmotic Release Oral Systems OROS Semi-permeable outer membrane with laser-drilled microscopic orifice; osmotic push compartment drives drug release Destruction of Osmotic Pump: Complete loss of rate-controlled delivery; laser orifice mechanism destroyed, precipitating massive dose dumping (e.g., Concerta / methylphenidate OROS).
Microencapsulated Bead Capsules Sprinkle capsules, coated granules Gelatin capsule filled with enteric-coated or sustained-release micro-beads Variable: Capsules may be opened and uncrushed beads sprinkled on acidic soft food (applesauce, yogurt); however, beads must never be crushed or chewed (e.g., Creon, Topamax sprinkle).
Sublingual / Buccal Forms SL Direct transmucosal absorption bypassing hepatic first-pass metabolism Loss of Bioavailability: Swallowed or crushed drug undergoes extensive hepatic first-pass extraction, rendering drug therapeutically ineffective.
Hazardous / Teratogenic Drugs Cytotoxic, immunosuppressive High-potency antineoplastic or teratogenic molecules Aerosol Exposure: Crushing generates airborne dust, exposing compounding personnel and environment to mutagens/teratogens (e.g., hydroxyurea, finasteride).
Practice Pearls & BCPPS Exam Traps
The Preserved Vehicle Trap: If you mix commercial tablets into Ora-Plus and Ora-Sweet (preserved aqueous vehicle, a w ≥ 0.60 a_w \ge 0.60 a w ≥ 0.60 ), the default BUD under USP <795> is 35 days , NOT 14 days. The 14-day limit applies strictly to non-preserved aqueous oral liquids stored in a refrigerator.
The Omeprazole Acid Trap: Omeprazole degrades within minutes in gastric acid ( p H < 2.0 pH < 2.0 p H < 2.0 ). Crushing enteric-coated omeprazole tablets and suspending them in standard Ora-Plus:Ora-Sweet ( p H ≈ 4.2 pH \approx 4.2 p H ≈ 4.2 ) destroys the drug. Omeprazole must be compounded in an alkaline vehicle containing 8.4% sodium bicarbonate (or SyrSpend SF Alka) to maintain p H > 8.0 pH > 8.0 p H > 8.0 , neutralizing stomach acid upon ingestion to permit duodenal absorption.
The OROS Concerta Trap: A common clinical error is attempting to crush Concerta (OROS methylphenidate) for pediatric administration via G-tube. Concerta consists of an insoluble plastic shell, an osmotic push engine, and a laser-drilled delivery port. Crushing it destroys the mechanism and causes immediate release of methylphenidate, precipitating severe tachycardia, hypertension, and agitation; G-tube patients must be converted to immediate-release liquid methylphenidate dosed 2 to 3 times daily.
The Shortest Expiration Rule: Never assign a default 35-day or 90-day BUD without inspecting the manufacturer lot expiration dates on all source ingredients. The assigned BUD cannot exceed the expiration date of any component.